ImmunoPrecise acquisition boosts antibody service

By Flora Southey

- Last updated on GMT


Related tags Biotechnology Dna

ImmunoPrecise Antibodies has acquired U-Protein Express, enabling it to offer microgram quantities of engineered antibodies to clients.

Under the terms of the agreement, Vancouver, Canada-based ImmunoPrecise will purchase U-Protein’s equipment, staff and client base for a combined cash and stock value of €6.83m ($10.32m).

ImmunoPrecise, which offers antibody engineering and production services including the development of mouse and rat monoclonal, and rabbit recombinant monoclonal antibodies, will employ U-Protein’s technologies to manufacture microgram quantities of ImmunoPrecise-engineered antibodies.

U-Protein provides mammalian recombinant proteins and antibodies for clients’ research and pre-clinical applications, and holds the rights to proprietary expression technology used in antibody production.

 “U-Protein Express can take ​[our] antibodies and grow them in their cell lines to delivery gram quantities to our customers,” ​said CEO Tom D’Ozario.

“For many of our clients, this expression of antibodies is a natural step in product development,” ​he added.

New clients, new market

D’Orazio told us he anticipates the acquisition will attract business, and diversify the firm’s revenue base.

“We have already seen a company become more interested in using us for contract research, once they found out we could be a one-stop-shop for more services,” ​he told us.

The acquisition of Utrecht, The Netherlands-based U-Protein, enables ImmunoPrecise to expand into the European marketplace, D’Ozario added.

“We foresee both commercial and technical expansion opportunities,” ​he said.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more